Evidence map›Paper›PMID 34423043›Full record

Observational studyBioMed research international2021

Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients with COVID-19.

Rui Han, Honghui Su, Gangwen Guo, Qiao Wang, Jiahui Ma, Zhenxing Li, Shitong Huang, Yuncheng Ni, Rong Hu, Dong Huang and 1 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Rui HanDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Honghui SuDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Gangwen GuoDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Qiao WangDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Jiahui MaDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Zhenxing LiDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Shitong HuangDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Yuncheng NiDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Rong HuDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Dong HuangDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.
Haocheng ZhouDepartment of Anesthesiology and Pain Medicine, The Third Xiangya Hospital, Central South University, Changsha, 410013 Hunan Province, China.ORCID https://orcid.org/0000-0001-6260-2005
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRespiratory failure is the leading cause of mortality in COVID-19 patients, characterized by a generalized disbalance of inflammation. The aim of this study was to investigate the relationship between immune-inflammatory index and mortality in PSI IV-V patients with COVID-19.

methodsWe retrospectively reviewed the medical records of COVID-19 patients from Feb. to Apr. 2020 in the Zhongfa Xincheng Branch of Tongji Hospital, Wuhan, China. Patients who presented high severity of COVID-19-related pneumonia were enrolled for further analysis according to the Pneumonia Severity Index (PSI) tool.

resultsA total of 101 patients diagnosed with COVID-19 were identified at initial research. The survival analysis revealed that mortality of the PSI IV-V cohort was significantly higher than the PSI I-III group (

conclusionProcalcitonin and neutrophil-to-lymphocyte ratio may potentially be effective predictors for mortality in PSI IV-V patients with COVID-19. Increased procalcitonin and neutrophil-to-lymphocyte ratio were associated with greater risk of mortality.

Indexed as

PandemicsSARS-CoV-2AgedAged, 80 and overBiomarkersChinaCohort StudiesCOVID-19FemaleHumansInflammationLymphocytesMaleMiddle AgedNeutrophilsPneumonia, ViralBiomarkersProcalcitonin

Identifiers

PMID34423043
PMCPMC8376466
OpenAlexW3193708040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.